These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 12964893)

  • 21. Detrol LA and Diropan XL for overactive bladder.
    Med Lett Drugs Ther; 2001 Apr; 43(1101):28. PubMed ID: 11283473
    [No Abstract]   [Full Text] [Related]  

  • 22. [Topical treatment with oxybutynin chloride in neurogenic incontinence].
    López Pereira P; Martínez MJ; Muguerza R; Jaureguizar E
    Cir Pediatr; 1993 Jan; 6(1):29-31. PubMed ID: 8499234
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The treatment of detrusor instability in post-menopausal women with oxybutynin chloride: a double blind placebo controlled study.
    Tapp AJ; Cardozo LD; Versi E; Cooper D
    Br J Obstet Gynaecol; 1990 Jun; 97(6):521-6. PubMed ID: 2198921
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An extended-release formulation of oxybutynin chloride for the treatment of overactive urinary bladder.
    Goldenberg MM
    Clin Ther; 1999 Apr; 21(4):634-42. PubMed ID: 10363730
    [TBL] [Abstract][Full Text] [Related]  

  • 25. S-oxybutynin.
    Drugs R D; 2002; 3(2):84-5. PubMed ID: 12001823
    [No Abstract]   [Full Text] [Related]  

  • 26. Low dose oxybutynin for the unstable bladder.
    Malone-Lee J; Lubel D; Szonyi G
    BMJ; 1992 Apr; 304(6833):1053. PubMed ID: 1586797
    [No Abstract]   [Full Text] [Related]  

  • 27. Management of overactive bladder in a difficult-to-treat patient with a transdermal formulation of oxybutynin.
    Saltzstein L
    Urol Nurs; 2005 Aug; 25(4):260-2. PubMed ID: 16225342
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Advantages for transdermal over oral oxybutynin to treat overactive bladder: Muscarinic receptor binding, plasma drug concentration, and salivary secretion.
    Oki T; Toma-Okura A; Yamada S
    J Pharmacol Exp Ther; 2006 Mar; 316(3):1137-45. PubMed ID: 16282521
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Cutaneous administration rather than swallowing].
    Schubert-Zsilavecz M
    Krankenpfl J; 2005; 43(7-10):186. PubMed ID: 16515258
    [No Abstract]   [Full Text] [Related]  

  • 30. [Clinical effects of oxybutynin hydrochloride (Pollakis)--especially in the treatment of pollakisuria, urgency and urinary incontinence].
    Yamauchi K; Ohashi K; Osanai H; Inagaki N; Yamaguchi S; Hashimoto H; Yachiku S
    Hinyokika Kiyo; 1990 Dec; 36(12):1485-90. PubMed ID: 2075888
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Preliminary evaluation of a new controlled-release oxybutynin in urinary incontinence.
    Radomski SB; Caley B; Reiz JL; Miceli PC; Harsanyi Z; Darke AC
    Curr Med Res Opin; 2004; 20(2):249-53. PubMed ID: 15006020
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Assessment of effectiveness of and tolerance to oxybutynin in the treatment of unstable bladder in women].
    Serrano Brambila EA; Quiroga Avila RG; Lorenzo Monterrubio JL; Moreno Aranda J
    Ginecol Obstet Mex; 2000 Apr; 68():174-81. PubMed ID: 10824450
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Transdermal oxybutynin for overactive bladder.
    Davila GW; Starkman JS; Dmochowski RR
    Urol Clin North Am; 2006 Nov; 33(4):455-63, viii. PubMed ID: 17011381
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety and tolerability of extended-release oxybutynin once daily in urinary incontinence: combined results from two phase 4 controlled clinical trials.
    Armstrong RB; Dmochowski RR; Sand PK; Macdiarmid S
    Int Urol Nephrol; 2007; 39(4):1069-77. PubMed ID: 17333521
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Can oxybutynin cause peripheral neuropathy?
    Patel HR; Albehussi S; Arya M; Miller RA
    J Urol; 2002 Aug; 168(2):646. PubMed ID: 12131334
    [No Abstract]   [Full Text] [Related]  

  • 36. Oxybutynin chloride in the management of idiopathic detrusor instability.
    Paulson DF
    South Med J; 1979 Mar; 72(3):374-5. PubMed ID: 424842
    [No Abstract]   [Full Text] [Related]  

  • 37. [Transdermal system].
    Krankenpfl J; 2005; 43(4-6):94. PubMed ID: 16171045
    [No Abstract]   [Full Text] [Related]  

  • 38. Comparison of a 10-mg controlled release oxybutynin tablet with a 5-mg oxybutynin tablet in urge incontinent patients.
    Nilsson CG; Lukkari E; Haarala M; Kivelä A; Hakonen T; Kiilholma P
    Neurourol Urodyn; 1997; 16(6):533-42. PubMed ID: 9353802
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intravesical instillation of oxybutynin in women with idiopathic detrusor instability: a randomised trial.
    Enzelsberger H; Helmer H; Kurz C
    Br J Obstet Gynaecol; 1995 Nov; 102(11):929-30. PubMed ID: 8534633
    [No Abstract]   [Full Text] [Related]  

  • 40. A short-term, multicenter, randomized double-blind dose titration study of the efficacy and anticholinergic side effects of transdermal compared to immediate release oral oxybutynin treatment of patients with urge urinary incontinence.
    Davila GW; Daugherty CA; Sanders SW;
    J Urol; 2001 Jul; 166(1):140-5. PubMed ID: 11435842
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.